Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23200551 | 1.00 | CNR1 (0.45) | CNR1FOLH1PPARAMMP9MMP14 | |
| SCHEMBL16758733 | 0.85 | FOLH1 (0.51) | CNR1FOLH1PPARAMMP9MMP14 | |
| SCHEMBL31307416 | 0.85 | ATM (0.60) | PPARACTSSSYK | |
| SCHEMBL6119036 | 0.83 | FOLH1 (0.48) | CNR1FOLH1PPARAMMP9MMP14 | |
| SCHEMBL5470004 | 0.81 | FOLH1 (0.48) | CNR1FOLH1PPARAMMP9MMP14 | |
| SCHEMBL28000850 | 0.81 | CTRB1 (0.52) | FOLH1SLC1A1MMECA1CA2 | |
| SCHEMBL15716271 | 0.81 | FOLH1 (0.48) | CNR1FOLH1PPARAMMP9MMP14 | |
| SCHEMBL2228752 | 0.81 | FOLH1 (0.48) | CNR1FOLH1PPARAMMP9MMP14 | |
| SCHEMBL28000849 | 0.81 | CTRB1 (0.52) | FOLH1SLC1A1MMECA1CA2 | |
| SCHEMBL2895518 | 0.81 | ALDH1A1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3802551-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198288-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | CNR1 4830/4885FOLH1 318/4885PPARA 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.